Tg Therapeutics (TGTX) Non-Current Debt (2010 - 2026)

Tg Therapeutics' Non-Current Debt history runs 13 years deep, the most recent figure standing at $745.1 million for Q1 2026.

• In Q1 2026, Non-Current Debt rose 204.47% year-over-year to $745.1 million; the TTM figure through Mar 2026 stood at $745.1 million (up 204.47% YoY), while the FY2025 annual figure was $245.6 million, changed 0.5% from the prior year.
• Non-Current Debt was $745.1 million for Q1 2026 at Tg Therapeutics, up from $245.6 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $745.1 million in Q1 2026 to a low of $67.2 million in Q1 2022.
• Historically, Non-Current Debt has averaged $181.8 million across 5 years, with a median of $101.3 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt climbed 0.48% in 2025, then jumped 204.47% in 2026.
• A 5-year view of Non-Current Debt shows it stood at $71.1 million in 2022, then jumped by 40.74% to $100.1 million in 2023, then jumped by 144.14% to $244.4 million in 2024, then rose by 0.5% to $245.6 million in 2025, then surged by 203.34% to $745.1 million in 2026.
• The last three Non-Current Debt figures came in at $745.1 million (Q1 2026), $245.6 million (Q4 2025), and $245.3 million (Q3 2025), per Business Quant data.